Kenvue Inc. (NYSE:KVUE) Shares Sold by Sage Mountain Advisors LLC

Sage Mountain Advisors LLC lowered its position in Kenvue Inc. (NYSE:KVUE) by 5.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,388 shares of the company’s stock after selling 825 shares during the period. Sage Mountain Advisors LLC’s holdings in Kenvue were worth $329,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Alerus Financial NA increased its holdings in Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC increased its stake in shares of Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after purchasing an additional 500 shares in the last quarter. Principle Wealth Partners LLC raised its position in shares of Kenvue by 3.7% during the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after purchasing an additional 500 shares during the last quarter. White Pine Capital LLC raised its position in shares of Kenvue by 1.0% during the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after purchasing an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its stake in Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after buying an additional 568 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock opened at $23.09 on Thursday. The business’s fifty day simple moving average is $21.77 and its 200-day simple moving average is $22.37. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $44.12 billion, a PE ratio of 43.56, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.55%. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KVUE. Piper Sandler increased their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Barclays decreased their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.